Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Galectin Therapeutics Inc (NASDAQ:GALT)

2.63
Delayed Data
As of 12:19pm ET
 +0.14 / +5.62%
Today’s Change
0.49
Today|||52-Week Range
3.68
+168.42%
Year-to-Date

Today’s Trading

Previous close2.49
Today’s open2.55
Day’s range2.51 - 2.64
Volume99,411
Average volume (3 months)175,573
Market cap$87.3M
Dividend yield--
Data as of 12:19pm ET, 10/20/2017

Growth & Valuation

Earnings growth (last year)+13.64%
Earnings growth (this year)+35.53%
Earnings growth (next 5 years)--
Revenue growth (last year)--
P/E ratioNM
Price/Sales--
Price/Book26.84

Competitors

 Today’s
change
Today’s
% change
CGIXCancer Genetics Inc+0.04+1.44%
TRILTrillium Therapeutic...+0.30+4.44%
VRMLVermillion Inc-0.01-0.66%
IDXGInterpace Diagnostic...-0.09-6.16%
Data as of 12:21pm ET, 10/20/2017

Financials

Next reporting dateNovember 9, 2017
EPS forecast (this quarter)-$0.13
Annual revenue (last year)$0.00
Annual profit (last year)-$21.4M
Net profit margin--

Profile

Sector
Health Technology
Industry
Biotechnology
President, CEO, Chief Medical Officer &
Director
Peter G. Traber
Chief Operating Officer &
Secretary
Harold H. Shlevin
Corporate headquarters
Norcross, Georgia

Forecasts